Core revenue growth excludes the impact of currency and the acquisitions and divestitures completed within the past 12 months.
We posted revenues of $1.48 billion during the quarter.
Revenues are up 8% on a reported basis and up 6% core.
Operating margins are a healthy 24.9%.
EPS of $0.98 is up 10% year-over-year.
Overall, COVID-19 tailwinds contributed just over 2 points of core growth.
Our Life Sciences and Applied Markets Group generated $671 million in revenue, up 8% on a reported basis and up 4% core.
The Agilent CrossLab Group came in with revenues at $518 million.
This is up a reported 9% and up 7% core.
For the Diagnostics and Genomics Group, revenues were $294 million, up 9% reported and up 7% core.
Growth was broad based, with NASD oligo manufacturing revenues up roughly 40%.
We generated $5.34 billion in revenue, up 3% on a reported basis and up nearly 1% core.
In Q1, we delivered 2% core growth, as you saw the first impact of COVID-19 in our business in China.
With 6% core growth, 8% reported in Q4, we're seeing business and economies start to recover.
In a very tough capex market, our LSAG instrument business declined only 2% for the year and returned to growth in the final quarter.
Full-year earnings per share grew 5% during fiscal 2020 to $3.28.
The full-year operating margin of 23.5% is up 20 basis points over fiscal 2019.
In total, the cell analysis business generated more than $300 million in revenue for us during the year, with double-digit growth in Q4 and continued strong growth prospects.
Similar to last year, I was talking about ramping up our new Frederick site facility, a $185 million capital investment.
We also recently announced additional $150 million investment to our future manufacturing capacity.
For the quarter, revenue was $1.48 billion, reflecting core revenue growth of 5.6%.
Reported growth was stronger at 8.5%.
Currency contributed 1.7%, while M&A added 1.2 points to growth.
From an end-market perspective, pharma, our largest market, showed strength across all regions and delivered 12% growth in the quarter.
The food market also experienced double-digit growth during the quarter, posting a 16% increase in revenue.
And as Mike noted earlier, our chemical and energy market exceeded our expectations, growing 3% after two quarters of double-digit declines.
Diagnostics and clinical revenue grew 1% during Q4, led by recovery in the U.S. and Europe.
For the quarter, China finished with 13% growth and ended the full year up 7%.
The Americas delivered a strong performance during the quarter, growing 5% with results driven by large pharma, food, and chemical and energy.
And in Europe, we grew 2% as we saw lab activity improved sequentially, benefiting from our on-demand service business in ACG, as well as from a rebound in pathology and genomics as elective procedures and screening started to resume.
Fourth quarter gross margin was 55%.
This was down 150 basis points year-over-year, primarily by a shift in revenue mix and an unfavorable impact of FX on margin.
In terms of operating margin, our fourth quarter margin was 24.9%.
This is down 20 basis points from Q4 of last year, as we made some incremental growth-focused investments in marketing and R&D, which we expect to benefit us in the coming year.
The quarter also capped off in full-year operating margin of 23.5%, an increase of 20 basis points over fiscal 2019.
Now wrapping up the income statement, our non-GAAP earnings per share for the quarter came in at $0.98, up 10% versus last year.
Our full-year earnings per share of $3.28 increased 5%.
In Q4, we had operating cash flow of $377 million, up more than $60 million over last year.
And in Q4, we continued our balanced capital approach, repurchasing 2.48 million shares for $250 million.
For the year, we repurchased just over 5.2 million shares for $469 million and ended the fiscal year in a strong financial position with $1.4 billion in cash and just under $2.4 billion in debt.
For the full year, we're expecting revenue to range between $5.6 billion and $5.7 billion, representing reported growth of 5% to 7% and core growth of 4% to 6%.
We expect operating margin expansion of 50 basis points to 70 basis points for the year, as we absorb the build out costs of the second line in our Frederick, Colorado NASD site.
And then helping you build out your models, we're planning for a tax rate of 14.75%, which is based on current tax policies and 309 million of fully diluted shares outstanding, and this includes only anti-dilutive share buybacks.
All this translates to a fiscal year 2021 non-GAAP earnings per share expected to be between $3.57 and $3.67 per share, resulting in double-digit growth at the midpoint.
Finally, we expect operating cash flow of approximately $1 billion to $1.05 billion and an increase in capital expenditures to $200 million, driven by our NASD expansion.
We have also announced raising our dividend by 8%, continuing an important streak of dividend increases, providing another source of value to our shareholders.
For Q1, we're expecting revenue to range from $1.42 billion to $1.43 billion, representing reported growth of 4.5% to 5.5% and core growth of 3.5% to 4.5%.
And first quarter 2021 non-GAAP earnings are expected to be in the range of $0.85 to $0.88 per share.

Summary:
We posted revenues of $1.48 billion during the quarter.
EPS of $0.98 is up 10% year-over-year.
Now wrapping up the income statement, our non-GAAP earnings per share for the quarter came in at $0.98, up 10% versus last year.
For the full year, we're expecting revenue to range between $5.6 billion and $5.7 billion, representing reported growth of 5% to 7% and core growth of 4% to 6%.
For Q1, we're expecting revenue to range from $1.42 billion to $1.43 billion, representing reported growth of 4.5% to 5.5% and core growth of 3.5% to 4.5%.
And first quarter 2021 non-GAAP earnings are expected to be in the range of $0.85 to $0.88 per share.